The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subj…

Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaRCC+6 more

~Estimated

~$10 – $8,750

Neomorph, IncNCT07300241

Phase 2

A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors

This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma…

Clear Cell Renal Cell Cancer (ccRCC)Clear Cell Renal CarcinomaClear Cell Renal Cell Carcinoma Metastatic+7 more

~Estimated

~$10 – $7,500

Kelly Fitzgerald, MDNCT07043608